These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34445279)

  • 1. Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma.
    Suk FM; Wang YH; Chiu WC; Liu CF; Wu CY; Chen TL; Liao YJ
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niemann-Pick type C2 protein regulates liver cancer progression via modulating ERK1/2 pathway: Clinicopathological correlations and therapeutical implications.
    Liao YJ; Fang CC; Yen CH; Hsu SM; Wang CK; Huang SF; Liang YC; Lin YY; Chu YT; Arthur Chen YM
    Int J Cancer; 2015 Sep; 137(6):1341-51. PubMed ID: 25754535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
    Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
    J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
    Wang W; Xu B; Li Q; Jiang D; Yan S
    Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CircRNA-SORE mediates sorafenib resistance in hepatocellular carcinoma by stabilizing YBX1.
    Xu J; Ji L; Liang Y; Wan Z; Zheng W; Song X; Gorshkov K; Sun Q; Lin H; Zheng X; Chen J; Jin RA; Liang X; Cai X
    Signal Transduct Target Ther; 2020 Dec; 5(1):298. PubMed ID: 33361760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells.
    Wang L; Zhan Y; Wu Z; Lin M; Jin X; Jiang L; Qiu Y
    Biomed Pharmacother; 2020 May; 125():110033. PubMed ID: 32187962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ID1-induced p16/IL6 axis activation contributes to the resistant of hepatocellular carcinoma cells to sorafenib.
    Niu LL; Cheng CL; Li MY; Yang SL; Hu BG; Chong CCN; Chan SL; Ren J; Chen GG; Lai PBS
    Cell Death Dis; 2018 Aug; 9(9):852. PubMed ID: 30154433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SOX9 enhances sorafenib resistance through upregulating ABCG2 expression in hepatocellular carcinoma.
    Wang M; Wang Z; Zhi X; Ding W; Xiong J; Tao T; Yang Y; Zhang H; Zi X; Zhou W; Huang G
    Biomed Pharmacother; 2020 Sep; 129():110315. PubMed ID: 32554246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zinc finger protein 703 induces EMT and sorafenib resistance in hepatocellular carcinoma by transactivating CLDN4 expression.
    Wang H; Xu H; Ma F; Zhan M; Yang X; Hua S; Li W; Li Y; Lu L
    Cell Death Dis; 2020 Apr; 11(4):225. PubMed ID: 32269215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin re-sensitizes hepatocellular carcinoma cells to sorafenib by inhibiting HIF-1α/PPAR-γ/PKM2-mediated glycolysis.
    Feng J; Dai W; Mao Y; Wu L; Li J; Chen K; Yu Q; Kong R; Li S; Zhang J; Ji J; Wu J; Mo W; Xu X; Guo C
    J Exp Clin Cancer Res; 2020 Jan; 39(1):24. PubMed ID: 32000827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIAA1199 promotes sorafenib tolerance and the metastasis of hepatocellular carcinoma by activating the EGF/EGFR-dependent epithelial-mesenchymal transition program.
    Xu Y; Xu H; Li M; Wu H; Guo Y; Chen J; Shan J; Chen X; Shen J; Ma Q; Liu J; Wang M; Zhao W; Hong J; Qi Y; Yao C; Zhang Q; Yang Z; Qian C; Li J
    Cancer Lett; 2019 Jul; 454():78-89. PubMed ID: 30980868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
    Dietrich P; Koch A; Fritz V; Hartmann A; Bosserhoff AK; Hellerbrand C
    Gut; 2018 Jul; 67(7):1328-1341. PubMed ID: 29275358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overriding sorafenib resistance via blocking lipid metabolism and Ras by sphingomyelin synthase 1 inhibition in hepatocellular carcinoma.
    Lu H; Zhou L; Zuo H; Le W; Hu J; Zhang T; Li M; Yuan Y
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):217-228. PubMed ID: 33226447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
    Chen J; Ji T; Zhao J; Li G; Zhang J; Jin R; Liu J; Liu X; Liang X; Huang D; Xie A; Lin H; Cang Y; Cai X
    Oncotarget; 2016 Jul; 7(27):41274-41284. PubMed ID: 27129180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.